Lung Cancer

Skip to main content

Lung Cancer

Targeted Therapy and Immunotherapy May Improve NSCLC Survival Rates

Lung Cancer

The Impact of Symptom Severity on Multidisciplinary Tumor Board Treatment Decisions

Meeting Highlights

Lung Cancer, ASCO Highlights

Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC

Phoebe Starr

Lung Cancer

2021 Midyear Review: Non–Small-Cell Lung Cancer

Case Reports, Lung Cancer, Adverse Events, Chemotherapy

Facial Edema Preceding Acute Renal Injury Linked to Pemetrexed Therapy in a Patient with Lung Cancer

Matthew S. Mattila, PharmD, BCPS, BCOP, Joel M. Lundberg, MD, FACP

Matthew S. Mattila, PharmD, BCPS, BCOP; Joel H. Lundberg, MD, FACP

FDA Updates, Lung Cancer

Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC

FDA Updates, Lung Cancer

FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations

FDA Updates, Lung Cancer

Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations

Lung Cancer

Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination

Lung Cancer

GEOMETRY Mono-1 Results: Capmatinib for the Treatment of MET Exon 14–Mutated NSCLC

1
2
3
4
5
6
7

Page 4 of 12
Results 31 - 40 of 116